Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
US Department of Justice
Deloitte
Harvard Business School
Fish and Richardson
Fuji
Express Scripts
McKesson

Generated: July 22, 2018

DrugPatentWatch Database Preview

Flibanserin - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for flibanserin and what is the scope of flibanserin freedom to operate?

Flibanserin
is the generic ingredient in one branded drug marketed by Sprout Pharms and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Flibanserin has eighty patent family members in thirty-one countries.

One supplier is listed for this compound.
Summary for flibanserin
International Patents:80
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 40
Clinical Trials: 16
Patent Applications: 397
Formulation / Manufacturing:see details
DailyMed Link:flibanserin at DailyMed
Pharmacology for flibanserin
Mechanism of ActionP-Glycoprotein Inhibitors
Synonyms for flibanserin
1-(2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-1H-benzo[d]imidazol-2(3H)-one
1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one
1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone
1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-(piperazinyl)ethyl)-2-benzimidazolinone
1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone
1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one
1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one
167933-07-5
2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-
2H-Benzimidazol-2-one,1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-
3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-1H-benzimidazol-2-one
3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
37JK4STR6Z
933F075
A810922
AC1OCF7H
Addyi
Addyi (TN)
AK326155
AKOS005146139
AM84577
API0006409
AT-16920
Bimt 17
BIMT 17 BS
Bimt-17
BIMT-17-BS
CHEBI:90865
CHEMBL231068
CS-4671
D02577
D0S9CB
DB04908
Ectris
Female Viagra (Street Name)
Female Viagra [Street Name]
Flibanserin (USAN/INN)
Flibanserin [USAN:INN]
FT-0659246
Girosa
Girosa (proposed trade name)
GTPL8182
HSDB 8278
HY-A0095
KS-00000293
L001463
MFCD00918402
MolPort-006-170-023
SC-28449
SCHEMBL247579
UNII-37JK4STR6Z
ZINC52716421

US Patents and Regulatory Information for flibanserin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for flibanserin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,782,403 Treating sexual desire disorders with flibanserin ➤ Try a Free Trial
7,183,410 Stable polymorph of flibanserin ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Express Scripts
Cantor Fitzgerald
Deloitte
Cipla
Accenture
Farmers Insurance
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.